Research

Advanced Medical Research Center

Advanced Medical Research Center(SENTANKEN)conducts basic studies aimed at overcoming cancer and lifestyle diseases and translational researches which applies the scientific finding to clinical medicine. It has three omics centers – genomics, proteomics, cellomics –and a biobank, collaborates within YCU and with other research institutions, and promote translational researches. AMRC is also involved in a number of R&D, working with the industry. Our goal is to make our research findings available to the society without delay.

Outline, Structure & Function of the Advanced Medical Research Center >
RESEARCH > ADVANCED MEDICAL RESEARCH CENTER

Message from the Director

The Advanced Medical Research Center (SENTANKEN) of Yokohama City University(YCU) was established in 2006. The assignment of SENTANKEN is to facilitate advanced medical research associated with diseases such as cancer and lifestyle-related diseases. SENTANKEN is focused on basic researches in the field of genomics, proteomics and cellomics, as well as translational researches, which can fill the gap between basic and clinical researches, and promotes not only intramural collaboration but also between government, industry and academia.

Our goal is to make an attractive YCU that can contribute to the community by delivering the research outcomes of our basic and clinical researches promptly to the citizens of Yokohama and by connecting these activities for the revitalization of industries in Yokohama.

Research News

2020-09-08

Polygenic architecture informs potential vulnerability to drug-induced liver injury

Drug-induced liver injury (DILI) is a leading cause of termination in drug development programs and removal of drugs from the market; this is partially due to the inability to identify patients who are at risk. In this study, we developed a polygenic risk score (PRS) for DILI by aggregating effects of numerous genome-wide loci identified from previous large-scale genome-wide association studies.
2020-07-20

Rapid quantitative screening assay for SARS-CoV-2 neutralizing antibodies using HiBiT-tagged virus-like particles

SARS-CoV-2 neutralizing antibodies confer protective immunity against reinfection. We have developed a rapid test for screening SARS-CoV-2 neutralization antibodies using genome-free virus-like particles incorporated with a small luciferase peptide, HiBiT. Their entry into LgBiT-expressing target cells reconstitutes NanoLuc luciferase readily detected by a luminometer.
2020-07-01

A pipeline for complete characterization of complex germline rearrangements from long DNA reads

Many genetic/genomic disorders are caused by genomic rearrangements. Standard methods can often characterize these variations only partly, e.g., copy number changes or breakpoints. It is important to fully understand the order and orientation of rearranged fragments, with precise breakpoints, to know the pathogenicity of the rearrangements.
 
Contact info

E-mail
sentan@yokohama-cu.ac.jp
Our location

3-9 Fukuura, Kanazawa-ku, Yokohama, Kanagawa 236-0004 Japan

Access >